Drugs / Pegylated Recombinant Human Endostatin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04413227 | Apr 2020 → May 2021 | non-small cell lung carcinoma | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated Recombinant Human Endostatin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04413227 ↗ |
| Known as | PEG-ENDO | “Pegylated Recombinant Human Endostatin（PEG-ENDO）” NCT04413227 ↗ |